Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare clinical syndrome characterized by an infrequent but immune-mediated life-threatening disease, with confusing clinical manifestations, rapidly deteriorating health, high morbidity and mortality and challenging diagnosis. Aim: The purpose of this study was to improve the recognition and understanding of HLH. Design: Retrospective observational cross-sectional study. Methods: Data were collected for all cases of adult patients diagnosed with HLH in a large cohort managed at a single medical center from January 2011 to December 2015. Results: The median age was 52 years (range 18-90 years) and 123 (60.0%) were male. Over 95% patients manifested fever, hyperferritinemia and elevated lactate dehydrogenase. Underlying triggers of HLH were as follows: 119 (58.0%) malignancies, 83 (40.5%) infections, 14 (6.8%) unknown triggers and 14 (6.8%) autoimmune disorders. The median overall survival was 55 days. And elderly patients (age !60 years) had a markedly worse survival compared with young patients (age <60 years) (median overall survival 24 days vs. 159 days, respectively; P <0.001). In a multivariable analysis, platelet <40 Â 10
Introduction
Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is an aggressive and life-threatening syndrome of excessive immune activation. The major feature of this disease is the aberrant function of natural killer cells and cytotoxic T cells. The common clinical presentations of HLH were prolonged fever, hepatosplenomegaly, cytopenia, hyperferritinemia, hypertriglyceridemia accompanied with or without hypofibrinogenemia and hemophagocytosis in the bone marrow, the liver, the spleen or the lymph nodes. 1 The first diagnostic guideline was published by HLH Study Group of the Histiocyte Society in 1991, and revised in 2004. 1, 2 HLH can be categorized as either primary onset or secondary onset. Primary HLH includes familial types of HLH, which is due to gene mutations involved in perforin and vesicle trafficking; and some cases of primary HLH are also associated with primary immunodeficiencies (e.g. Chediak-Higashi, Griscelli syndrome, Hermansky-Pudlak and X-linked lymphoproliferative disease). 3 Without HLH-specific therapy, such as immunosuppressive chemotherapy and stem cell transplantation, the clinical outcome of primary HLH is fatal. 1 In secondary HLH, acquired defects in lymphocyte and NK cell cytotoxic function underlie the pathological mechanisms, and the clinical manifestation can be further complicated by the accompied infection, malignancy or autoimmune disfuntion. 3 HLH most frequently affects infants from birth to 18 months of age, but the disease is also observed in children and adults of all ages, 4 especially with a trend of more and more cases seen in adult. However, the mechanism, diagnosis and therapeutic approaches of adult-onset HLH is poorly understood, which has been highlighted only recently by several published series of cases. [5] [6] [7] HLH patients present with a wide spectrum of clinical manifestations, rapidly exacerbating conditions, as well as considerable mortality. Because of its heterogeneous etiology and nonspecific clinical and laboratory findings, the diagnosis of adult-onset HLH is often delayed or unrecognized. 8 We analyzed the clinical data of a large cohort of adult patients diagnosed secondary HLH following standardized selection criteria. Our data demonstrated the variable clinical spectrums of these patients, and determined the poor prognosis factors related to HLH patient's survival.
Materials and methods

Patients and selection criteria
Eligibility criteria included age over 18 years and morphologic evidence of phagocyte in the bone marrow. In addition, patients were eligible if they met the 2004 Histiocyte Society Criteria for HLH diagnosis (HLH-2004) . 1 Thus, patients were diagnosed with HLH when they satisfied at least five of the following criteria: (1) fever (!38.5 C for !7 days); (2) splenomegaly; (3) cytopenias affecting at least two of three lineages (i.e. hemoglobin <90 g/l, platelet count <100Â10 9 /l, neutrophil count <1.0Â10 9 /l); (4) hypertriglyceridemia (!3 mmol/l) and/or hypofibrinogenemia ( 1.5 g/l); (5) hemophagocytosis in bone marrow, spleen, liver or lymph nodes; (6) hyperferritinemia (!500 lg/l); (7) low or absent NK-cell cytotoxicity; and (8) elevated level of serum soluble CD25 (i.e. soluble interleukin-2 receptor !2400 IU/ml). Since the tests for soluble CD25 levels and NK cell activity were not available in our institute, diagnosis was done when five out of the other six criteria fulfilled.
Patients were categorized as young group if they were younger than 60 years. Elderly group included patients who were not <60 years. Informed consents were obtained from all patients before the collection of patients' information and serum samples for analyses. This study was approved by the institutional review board of the First Affiliated Hospital of Medical School of Zhejiang University.
Laboratory and imaging examination
The initial tests which are helpful in evaluating HLH will have already been done as part of the evaluation of an unexplained febrile illness with multiple involved organs. Others, including serum ferritin, triglycerides and immunologic studies, should be done immediately.
We do the following tests in all patients at the time of diagnosis: complete blood count with differential [white blood cell (WBC), neutrophil (Neu), lymphocyte (Lym) and platelet (PLT) count, concentrations of hemoglobin (Hb)], coagulation function test [fibrinogen (Fib), activated partial thromboplastin time (APTT), prothrombin time (PT)], biochemical examination [alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), globulin (GLB), alkaline phosphatase (AKP), adenosine deaminase (ADA), total bilirubin (TB), direct bilirubin (DB), indirect bilirubin (IB), c-glutamyl transpeptidase (c-GT), triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), lactate dehydrogenase (LDH), sodium, serum ferritin (SF), C-reactive protein (CRP) and
Identifying signs of infection and specific organ injury could help diagnose HLH, as well as for management of organ-specific complications. Based on the degree of suspicion for the presence of HLH, we perform the following studies in all patients: virology, bacteriology, mycology, bone marrow morphology, flow cytometry, bone marrow tissue immunohistochemical staining, imaging tests for liver, spleen, lymph nodes including B ultrasound examination and computerized tomography (CT). Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infection were diagnosed based on the detection of immunoglobulin M (IgM) antibodies or high levels of EBV or CMV DNA. 9 
Statistical analysis
Overall survival (OS) was defined as the time between the onset of acute illness and the date of death from any trigger or from the date of last follow-up if definitive date of death cannot be determined. Categorical variables were compared using nonparametric tests and the Pearson's Chi-square test and continuous variables, such as age, were compared using Mann-Whitney U tests. Survival curves were estimated by the Kaplan-Meier method and compared using the long-rank test. Multivariate analysis was performed using the cox-regression method. Results were considered significant at P < 0.05 based on twosided tests. All data analyses were performed using the SPSS version 19.0 statistical software program (SPSS, Chicago, IL).
Results
Clinical and laboratory examination characteristics
A total of 205 patients were diagnosed HLH between January 2011 and December 2015 and were included in this study. The median age at the time of diagnosis was 52 years (range 18-90 years) with a gender bias to male patients (123 patients, 60.0%). The clinical and laboratory findings of patients according to HLH-2004 criteria are presented in Table 1 . The most common clinical manifestations were fever (98.5%), followed by hyperferritinemia (97.5%), cytopenias (92.1%) and splenomegaly (87.0%). The median temperature, ferritin, triglycerides and fibrinogen level on presentation were 39. /l and Hb <90 g/l) in at least two cell lineages.
In addition to the diagnostic criteria findings, the most common biochemical indication was high LDH (>250 U/l, 95.4%), followed by elevated level of ADA (>18 U/l, 92.1%), AST (>40 U/l, 91.7%) and b 2 -M (>2300 lg/l, 91.4%), with a median level of 966.5 U/l (108-17 389 U/l), 55 U/l (8-364 U/l), 197 U/l (15-13 335 U/l) and 4875 lg/l (1170-25 140 lg/l), respectively. Median albumin was 24.5 g/l (range 13.3-38.3 g/l) and median c-GT was 164 U/l (10-1881 U/l). Hyperbilirubinemia (total bilirubin level >21 lmol/l) accounted for 68.3% of patients. And 62.9 and 42.4% of the patients had prolonged levels of APTT (10 s greater than control) and PT (3 s greater than control). Increased CRP (>20 mg/l) was observed in 177 (88.1%) of 201 patients, with a median level of 75.3 mg/l (0.5-793.5 mg/l) ( Figure 1 ).
The laboratory results of patients who had HLH were compared according to the ages (Table 2 ) and the frequency of hypertriglyceridemia was lower than that of the other items of HLH-2004 criteria. Comparison of young group and elderly group revealed that there was a significant difference only in triglycerides according to the HLH-2004 criteria (P < 0.001). In addition, the level of TG and ALT were higher in the younger than that in the elderly (P < 0.001 and P < 0.001, respectively), the level of WBC, neutrophil, and b 2 -M, however, were lower in the young group (P ¼ 0.015, P < 0.001 and P ¼ 0.002, respectively) ( Table 2 ).
Underlying diseases of HLH
The distribution of the underlying diseases in 205 patients with HLH was presented in Table 3 . The majority of underlying diseases in HLH patients were malignancies (119/205, 58.0%), followed by infections (83/205, 40.5%), autoimmune disorders (14/205, 6.8%) and unknown triggers (14/205, 6.8%). And some patients had more than one trigger, including 12 patients with both malignancy and infection (5.9%), 1 patient with infection and an autoimmune disorder (0.5%). Among the malignancy-associated cases, the most frequent cancer was invasive T-cell lymphoma (37/119, 31.1%), followed by NK/T-cell lymphoma (32/119, 26.9%) and aggressive B-cell lymphoma (32/119, 26.9%). Of the infection-associated cases, viral infections were the most common trigger, including 11 patients with EBV, 8 patients with hepatitis B virus (HBV). Additional viruses identified included CMV, human immunodeficiency virus (HIV), influenza virus (H1N1, H3N2) and new bunia virus. Bacterial infections were observed in 30 patients, including 6 patients with staphylococcus aureus, 7 with escherichia coli, 7 with acinetobacter baumannii, and more than one infection in 14 patients. The most frequent autoimmune diseases associated with HLH in our patient population included adult Still's disease, systemic lupus erythematosus and kikuchi disease. In addition, there were cases diagnosed with thrombotic thrombocytopenic purpura, Castleman's disease, which were unusual reasons leading to HLH in literature. The distribution of the underlying disorders in patients in two different age groups was presented in Figure 2 .
Treatment
Treatment variables included underlying diseases of HLH and physician management decisions. Among the 119 patients with hematological malignancy-associated HLH, 71 patients received combination chemotherapy regimens or other cytotoxic drugs such as etoposide, methotrexate or L-asparaginase and 15 of these patients also received rituximab. Thirty-four patients received maintenance therapy with R-CHOP or CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisone with or without rituximab). Twenty-two patients received supportive care without chemotherapy because of poor performance status.
Patients with infection-associated HLH were treated with the suitable antiviral, antibiotic, antifungal or antituberculotic therapy targeting suspected or confirmed pathogens. In addition, 38 of these patients were given steroids with the use of intravenous immunoglobulin (IVIG). Autoimmune-associated HLH cases were treated with steroids and/or IVIG. Cases of unknown triggers were treated with various combinations of steroids, IVIG and supportive care.
Outcome and survival analysis
With survival data available of the 205 patients, the median OS of the entire cohort was 55 days (95% CI 16.9-93.1) ( Figure 3A ). Eightynine patients died within the first 30 days (43.4%). The most common trigger of death was multiple organ dysfunction syndrome, followed by respiratory failure, disseminated intravascular coagulation (DIC) and septic shock. The median OS of patients in the young group was 159 days, and 52 patients were diagnosed as malignancy-associated HLH among the 71 dead patients, including 21 cases with NK/T cell lymphoma, 15 cases with T-cell lymphoma, 8 cases with B-cell lymphoma, 4 cases with myelodysplastic syndrome (MDS) and 4 cases with acute leukemia. The OS of elderly group was 24 days, and 57.9% (44/76) patients died within the first 30 days. In addition, 42 patients died of malignancies and 13 died of infections among 61 dead patients. OS had a great significance between the two groups (P < 0.001) ( Figure 3B ). With different triggers, the median OS between malignancy group and infection group also had a great significance (28 days vs. undefined, P < 0.001) ( Figure 4A ). In addition, the median OS in the elderly group was much shorter than that in the young group, no matter patients with malignancy or infection (P ¼ 0.002) ( Figure 4B and C) .
We also analyzed the potential risk indicators which might affect the prognosis of HLH. Multivariate analysis confirmed PLT <40 Â 10 9 /l (HR ¼ 2.534; 95% CI 1.152-5.573; P ¼ 0.021), PT prolonged >3 s (HR ¼ 1.909; 95% CI 1.127-3.234; P ¼ 0.016) and malignancy (HR ¼ 1.614; 95% CI 1.008-2.582; P ¼ 0.046) as predictors of death (Table 4) . Besides, DB >14 lmol/l (HR ¼ 2.768; 95% CI 1.022-7.495; P ¼ 0.045) was the only independent risk factor for poor survival in elderly patients, and malignancy reported that serum ferritin levels >50 000 lg/l could be observed in conditions including renal failure, hepatocellular injury, infections and hematologic malignancies, and was not specific for HLH in adults. Wormsbecker et al. 25 found ferritin >3000 lg/l was uncommon in adult HLH patients and most was observed in adults with iron overload and liver disease. Thus, ferritin levels with high specificity is useful diagnostically, especially in children; whereas in adults, evaluating other potential causes of extremely high ferritin levels is important. In our study, 76 of 202 patients (37.6%) had ferritin levels >10 000 ng/ml, and 57 patients (28.2%) had ferritin levels between 3000 and 10 000 ng/ml. It is highlighted to identify the cutoff of ferritin in adults with HLH. Although a very high level of ferritin is helpful in proposing the possibility of HLH, disease activity in some patients may correlate more closely with soluble IL-2 receptor (sIL-2R or sCD25) ferritin ratio rather than with ferritin. 26 Interestingly, macrophages are a primary source of ferritin, which may explain the association between HLH and very high levels of ferritin. 27 Hypertriglyceridemia is due to severe involvement of liver, and triglycerides may not be increased until the liver has been affected for a period of time. In a review of patients with secondary HLH, 68% had increased triglycerides at the time of diagnosis or during the course of the disease. 28 Coagulation abnormalities including low fibrinogen levels are often due to impaired hepatic synthetic function and/or DIC. On autopsy, the livers of HLH patients display chronic persistent hepatitis with periportal lymphocytic infiltration. 29 The common triggers in adult patients with HLH include infection, malignancy, rheumatologic and immunodeficiency syndromes. The most frequent underling disease in our population was hematological malignancy (58.0%), followed by infection (40.5%). Among the different possible etiologies of secondary HLH, malignancy was the most common trigger in the hematologic department. Ramos-Casals et al.'s 6 recent review of adult HLH reported that infections constituted the main trigger of HLH in 50.4% of cases followed by malignancy in 47.6%. And our results are similar to a retrospective analysis conducted at the Mayo Clinic and a multicenter study from France. 5, 7 In a cohort of 162 adults with HLH, the most common trigger was hematologic malignancies, primary non-Hodgkin lymphoma, seen in 92 (57%) patients. 7 Our study showed that lymphomas were particularly common in malignancy group at any age, the same with the two study from Mayo Clinic and France. 5, 7 which may explain that malignancy had a high level in both younger and elderly groups. Malignancy-associated HLH in T-cell lymphomas is related to the release of several cytokines by the neoplastic T cells; and the activated T cells surrounding the neoplastic B cells secreting these cytokines leads to HLH in B-cell lymphomas. 30 That's why the cytokine storm is more intensive in T-cell lymphomas than that in B-cell lymphomas, so is the high incidence of cytokine storm. In addition, it is reported that hyperbilirubinemia or jaundice were significantly associated with adverse outcome in lymphoma associated HLH, and more specifically T-cell lymphoma. 31 And ADA plays an important role in immune regulation, and has been considered as a nonspecific marker of T-cell proliferation and activation. 32 Chen et al. 33 found that the cutoff of ADA was 89.25 U/l for lymphoma-associated HLH, with a sensitivity and specificity of 85.0 and 76.2%, respectively.. However, ADA level >89 U/l was only in 36 patients (22.0%), with 164 patients tested in our analysis. Moreover, many patients with malignancy-associated HLH appear to have an acute infectious trigger and the HLH in this condition is often more immediately life-threatening than the malignancy itself. Thus, it is important to underline that not all patients had only one trigger. Infection is also a common trigger of HLH. The most common infectious trigger for HLH is viral infection, specially with EBV. 6 In a series of 30 patients who had EBV-DNA test, 10 were found to be positive. 34 Although less common, HLH may also occur in the infections due to bacteria (e.g. Brucella, gram negative bacteria, tuberculosis), parasites (e.g. Leishmaniasis, malaria) and fungi (e.g. Candida albicans, aspergillus). 6, 35, 36 HLH can be triggered by the setting of rheumatologic disorders, also called macrophage activation syndrome (MAS), and may develop at any time during the course of diseases, such as upon presentation, during therapy or in association with a concurrent infection. Patients with rheumatologic diseases, for instance, who had anti-TNF agents as treatment and develop HLH may be infected with mycobacterium tuberculosis, CMV, EBV and other bacteria. 37 When rheumatoid arthritis patients have MAS as a presenting manifestation, the diagnosis may be challenging. Other autoimmune diseases associated with HLH include Sjö gren's syndrome, ankylosing spondylitis, vasculitis, dermatomyositis, systemic sclerosis, antiphospholipid syndrome and sarcoidosis. 38 Sometimes HLH occurs with a concurrent infection or a lymphoproliferative syndrome. 39 Most patients with HLH are seriously ill with multiorgan involvement, cytopenias, liver function abnormalities and neurologic symptoms. Patients may have already experienced a clinical deterioration without a clear diagnosis before the possibility of HLH is raised. The diagnostic approach is similar in infants, children and adults. 40 The physical examination should focus on identifying rashes, lymphadenopathy, hepatosplenomegaly and neurologic abnormalities. And other organ involvement including cardiac and respiratory is also necessary. Due to the high mortality of HLH, it should be noted that initiate treatment is necessary even if diagnostic criteria is not met. Thus, treatment is appropriate for some who do not meet the strict diagnostic criteria but for whom there is a high degree of clinical suspicion for HLH. There was no standard management for all HLH patients and treatment varied widely based on the HLH underlying diseases, functional capacity and clinical manifestation. The treatment is to halt any underlying trigger and control the overaction of immune system. Often the greatest barrier to treatment is delayed diagnosis. When HLH is triggered by an acute infection or rheumatologic condition, disease-specific treatment is appropriate because this may remove the stimulus for immune activation. Patients who are less acutely ill may undergo treatment for a triggering condition alone rather than HLHspecific therapy and these patients may be able to avoid potentially toxic therapy. Patients with malignancy-induced HLH require the treatment of the underlying malignancy. Previous reports have suggested that young adult patients receiving early etoposide treatment have a better prognosis than those not treated with etoposide or treated late. 41, 42 However, Shabbir et al. 43 found immunosuppression with corticosteroids and/or cyclosporine remains the foundation of early management as it can control systemic inflammation. In this study, patients once diagnosed of malignancy, they would receive anti-malignancy treatment rather than treatment directed to HLH, for HLH was resulted from lymphoma, leukemia and MDS, except some with poor performance status. And patients with infection-associated HLH were treated with antibiotics, combined with IVIG in severe cases. Viral infections, especially EBV, play a well recognized role as continuous trigger of the related cytokine storm. Thus, specific and effective antiviral treatment should be pursued in these patients, and rituximab alone or in combination with chemotherapy has been employed for EBV-induced HLH successfully. 44 Prognosis is worse in adults with an underlying malignancy, low platelet count, elevated AST and elevated LDH and age >50 years, which was shown in a review of 162 adults with HLH. 45 Treatment with etoposide was associated with better survival. Other reports have also demonstrated a worse prognosis when HLH is associated with malignancy, especially T-cell lymphomas. 5, 35 Untreated patients with HLH have a survival of months, due to progressive multi-organ failure. The 30-day mortality from symptom onset in our cohort was 43.4, 34.9 (45/129) and 57.9% (44/76) in young and elderly groups, respectively. As is well known that HLH patients have a high mortality rate, due to lacking of clinical suspicion as well as genetic and molecular studies, especially when the elderly with poor performance status. In our study, elderly group had a worse survival compared with young group, and malignancy group had a much shorter OS than infection group. On the other hand, a number of survivals have a long survive time due to the well reaction to the treatment of HLH. Intriguingly, we found patients with PLT <40 Â 10 9 /l, PT prolonged >3 s and malignancy had shorter OS by using multivariate analysis. For elderly patients, DB >14 lmol/l was the sole predictor of poor OS. On the other hand, malignancy, PT prolonged >3 s and LDH >1000 U/l were the poor predictors for the young patients. A study observed that thrombocytopenia was a consistent prognostic factor for mortality in adult HLH, which may result from consumption through hemophagocytosis, hypersplenism and DIC. 45 Limitations to this study are as follows. First, it is a retrospective cohort and dependent on case selection criteria. This limitation was minimized by using multiple databases to identify potential cases. Second, adult HLH were defined by using the HLH-2004 criteria. However, these criteria may be too strict for adults with secondary HLH. Patients presented with transaminitis, coagulopathy and high level of LDH are not included in the HLH-2004 criteria. Therefore, further multicenter or prospective research with a larger sample size is needed to refine adult HLH diagnostic criteria.
HLH is a disastrous disease which has gained increasing attention over the last decade. Most patients with HLH are seriously ill with multiorgan involvement. This study analyzed a single center's experience with adult HLH, which should be early recognized and treated, especially when patients encountered PLT <40 Â 10 9 /l, PT prolonged >3 s and malignancy. Elderly patients need more attention due to organs dysfunction and poor status. Further studies are needed to improve the diagnostic criteria, develop novel therapeutic regimens and determine the poor prognosis factors related to OS for HLH in adults. 
